Intensification Treatment of Ovarian Cancer by PIPAC

The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and visually detectable peritoneal carcinomatosis. The main questions are whether repeated PIPAC increases the rate of complete surgical cytoreduction (CRS R0) and whether it improves disease control, survival outcomes, and safety compared with standard combined treatment including a single PIPAC procedure. Participants will undergo screening, intraoperative randomization

Trial Details

NCT ID
NCT07514494
Phase
PHASE2
Sponsor
Moscow Regional Oncological Dispensary
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • PIPAC
Locations (sample)
  • Balashikha, Russia|55.79479,37.94794

Key Eligibility Criteria

  • Female, age 18-75 years.
  • Histologically verified ovarian cancer with peritoneal carcinomatosis.
  • FIGO stage IIIB or IIIC.
  • visually detectable peritoneal carcinomatosis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →